YCMGA
ACAD icon

York Capital Management Global Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

York Capital Management Global Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-120,004
Closed -$3.35M – 70
2017
Q2 		$3.35M Buy
+120,004
New +$3.58M 0.07% 69

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

York Capital Management Global Advisors's ACAD Position: Q3 2017 in Review

York Capital Management Global Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 120,004 shares — an estimated $3.35M sold.

York Capital Management Global Advisors first reported a position in ACAD in Q2 2017 and held it in 1 quarter. The position peaked at $3.35M in Q2 2017. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

  • York Capital Management Global Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • York Capital Management Global Advisors sold 120,004 Acadia Pharmaceuticals shares in Q3 2017, an estimated $3.35M.
  • York Capital Management Global Advisors first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • York Capital Management Global Advisors's Acadia Pharmaceuticals position peaked at $3.35M in Q2 2017.
  • 212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on York Capital Management Global Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.